CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 99 enrolled
Drug / intervention
Pranactin citric solutionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01623154
NCT01623154Phase 4Completed

A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms

Otsuka America Pharmaceutical·interventional·Posted Jun 19, 2012·Updated Feb 23, 2015

In Brief

A Phase 4 clinical trial evaluating Pranactin citric solution for Bacterial Infection Due to Helicobacter Pylori (H. Pylori). Completed, enrolled 99 participants across 3 sites.

Detailed Summary

The purpose of this study is to compare between the POCone® to the UBiT®-IR300 in measuring 13CO2/12CO2 ratio in breath samples when used together with the BreathTek® UBT (urea breath test) Kit and the pUHR-CA web-based software program in identifying H. pylori infection in pediatric subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 19, 2012
Enrollment StartJul 1, 2012
Primary CompletionMar 1, 2013
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.0 years ago

Interventions

Pranactin citric solutionother

All patients were required to drink the pranactic citric solution to diagnose H.pylori.